Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?
Pollock
David M
DM
Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912-2500, USA. dpollock@mcg.edu
Boesen
Erika I
EI
Black
Stephen M
SM
D000818:Animals; D016503:Drug Delivery Systems; D055808:Drug Discovery; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D011485:Protein Binding; D017466:Receptors, Endothelin / Q000378:metabolism
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D017466:Receptors, Endothelin